Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ayana R Kumar"'
Autor:
Ayana R. Kumar, Bhagyalakshmi Nair, Adithya Jayaprakash Kamath, Lekshmi R. Nath, Daniela Calina, Javad Sharifi-Rad
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-15 (2024)
Abstract Metabolic dysfunction-associated steatohepatitis (MASH) and progression to hepatocellular carcinoma (HCC) exhibits distinct molecular and immune characteristics. These traits are influenced by multiple factors, including the gut microbiome,
Externí odkaz:
https://doaj.org/article/9c8a6e1968304acb827c35e2b77b729e
Publikováno v:
Recent Patents on Anti-Cancer Drug Discovery. 18:268-291
Abstract: Green nanotechnology can offer notable advantages over the conventional drug delivery methods in terms of improved drug stability, drug-carrying capacity, site-specificity, and feasibility to apply different routes of administration with le
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 23:882-893
Objectives: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and accounts for ~90% of cases, with an approximated incidence of >1 million cases by 2025. Currently, the backbone of HCC therapy is the oral multi-kinase inhibitor,
Autor:
Aswathy R. Devan, Ayana R. Kumar, Bhagyalakshmi Nair, Nikhil Ponnoor Anto, Amitha Muraleedharan, Bijo Mathew, Hoon Kim, Lekshmi R. Nath
Publikováno v:
Pharmaceuticals, Vol 14, Iss 7, p 656 (2021)
Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to
Externí odkaz:
https://doaj.org/article/d8561ce756e24227880e0c26a9940b81
Autor:
Lekshmi R Nath, Bhagyalakshmi Nair, G. K. Pradeep, M. Murali, Aswathy R. Devan, Ayana R Kumar, K. Pavithran
Publikováno v:
Clinical and Translational Oncology. 24:407-431
An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engine
Publikováno v:
Current cancer drug targets. 22(9)
Mucin 1 (MUC 1) is a highly glycosylated tumor-associated antigen (TAA) overexpressed in hepatocellular carcinoma (HCC). This protein plays a critical role in various immune-mediated signaling pathways at its transcriptional and post-transcriptional
Autor:
Amitha Muraleedharan, Bijo Mathew, Nikhil Ponnoor Anto, Ayana R Kumar, Bhagyalakshmi Nair, Aswathy R. Devan, Hoon Kim, Lekshmi R Nath
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 656, p 656 (2021)
Pharmaceuticals, Vol 14, Iss 656, p 656 (2021)
Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to
Autor:
Jasmine Baby, Bhagyalakshmi Nair, Lekshmi R Nath, Thanatharayil Sathian Aishwarya, Ayana R Kumar, Aswathy R. Devan, Jaggaiah N. Gorantla
Publikováno v:
Journal of Food Biochemistry. 45
Chemopreventive approaches with food-derived phytochemicals are progressively rising as a significant aspect of tumor management and control. Herein, we have showcased the major phytoconstituents belonging to the group of flavanoid, as anti-cancer ag
Publikováno v:
Mol Biol Rep
Cancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the im
Autor:
Lekshmi R Nath, Jaggaiah N. Gorantla, T S Aishwarya, Aswathy R Devan, Ayana R Kumar, Bhagyalakshmi Nair
Publikováno v:
Current pharmaceutical biotechnology. 23(2)
Months after WHO declared COVID-19 as a Global Public Health Emergency of International Concern, it does not seem to be flattening the curve as we are still devoid of an effective vaccine and treatment modality. Amid such uncertainty, being immune is